ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,307.01
0.00%
Dow Jones
39,671.04
0.00%
US Dollar vs MXN
16.6298
-0.21%
Brent Oil
82.545
1.24%
Bitcoin
69,118.76
0.06%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Pyxis Oncology Inc (PYXS)

  7. Pyxis Oncology Inc (PYXS) Noticias

PYXS

Pyxis Oncology (PYXS)

Pyxis Oncology Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PYXS
FechaHoraFuenteTítuloSímboloCompañía
14/05/202407:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PYXSPyxis Oncology Inc
14/05/202406:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
14/05/202406:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024NASDAQ:PYXSPyxis Oncology Inc
09/05/202406:30GlobeNewswire Inc.Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:PYXSPyxis Oncology Inc
28/03/202415:30GlobeNewswire Inc.Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PYXSPyxis Oncology Inc
27/03/202406:30GlobeNewswire Inc.Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsNASDAQ:PYXSPyxis Oncology Inc
21/03/202406:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023NASDAQ:PYXSPyxis Oncology Inc
13/03/202407:00GlobeNewswire Inc.Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFANASDAQ:PYXSPyxis Oncology Inc
08/03/202415:03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PYXSPyxis Oncology Inc
07/03/202415:30GlobeNewswire Inc.Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024NASDAQ:PYXSPyxis Oncology Inc
05/03/202415:45GlobeNewswire Inc.Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingNASDAQ:PYXSPyxis Oncology Inc
27/02/202407:00GlobeNewswire Inc.Pyxis Oncology Announces $50 Million Private PlacementNASDAQ:PYXSPyxis Oncology Inc
29/12/202315:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
06/12/202315:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
28/11/202306:00GlobeNewswire Inc.Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical OfficerNASDAQ:PYXSPyxis Oncology Inc
07/11/202315:30GlobeNewswire Inc.Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdateNASDAQ:PYXSPyxis Oncology Inc
27/10/202315:34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PYXSPyxis Oncology Inc
27/09/202308:18GlobeNewswire Inc.Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023NASDAQ:PYXSPyxis Oncology Inc
05/09/202316:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PYXSPyxis Oncology Inc
31/08/202315:01GlobeNewswire Inc.Pyxis Oncology to Participate in Two Upcoming Investment ConferencesNASDAQ:PYXSPyxis Oncology Inc
24/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PYXSPyxis Oncology Inc
23/08/202316:30Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PYXSPyxis Oncology Inc
23/08/202316:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PYXSPyxis Oncology Inc
23/08/202316:28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PYXSPyxis Oncology Inc
23/08/202307:35GlobeNewswire Inc.Pyxis Oncology Successfully Completes Acquisition of ApexigenNASDAQ:PYXSPyxis Oncology Inc
11/08/202306:26Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PYXSPyxis Oncology Inc
11/08/202306:00GlobeNewswire Inc.Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate UpdateNASDAQ:PYXSPyxis Oncology Inc
01/08/202315:01GlobeNewswire Inc.Pyxis Oncology to Present at BTIG Virtual Biotechnology ConferenceNASDAQ:PYXSPyxis Oncology Inc
28/07/202309:18Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:PYXSPyxis Oncology Inc
30/06/202315:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PYXSPyxis Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:PYXS

Su Consulta Reciente

ASX
KPTRA
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados